Myovant Sciences's Total Assets for the quarter that ended in Mar. 2022 was $520.0 Mil.
During the past 12 months, Myovant Sciences's average Total Assets Growth Rate was 114.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 71.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 73.50% per year.
During the past 7 years, Myovant Sciences's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was 56.40%. And the median was 71.90%.
Total Assets is connected with ROA %. Myovant Sciences's annualizedROA % for the quarter that ended in Mar. 2022 was -42.18%. Total Assets is also linked to Revenue through Asset Turnover. Myovant Sciences's Asset Turnover for the quarter that ended in Mar. 2022 was 0.10.
Myovant Sciences Total Assets Historical Data
The historical data trend for Myovant Sciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Total Assets
119.10
172.98
105.93
725.03
520.01
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Total Assets
725.03
727.77
679.54
604.29
520.01
Myovant Sciences Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Myovant Sciences's Total Assets for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Myovant Sciences's Asset Turnover for the quarter that ended in Mar. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Myovant Sciences Total Assets Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 491,528 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
